You just read:

Vedanta Biosciences Announces License Agreement with Janssen and Johnson & Johnson Innovation for Microbiome Pharmaceutical Candidate for Inflammatory Bowel Disease

News provided by

Vedanta Biosciences

Jan 13, 2015, 08:00 ET